Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury.
Details
Serval ID
serval:BIB_1487E4A9A0D7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury.
Journal
The New England journal of medicine
Working group(s)
STARRT-AKI Investigators, Canadian Critical Care Trials Group, the Australian and New Zealand Intensive Care Society Clinical Trials Group, the United Kingdom Critical Care Research Group, the Canadian Nephrology Trials Network, and the Irish Critical Care Trials Group
Contributor(s)
Bellomo R., Eastwood G.M., Peck L., Young H., Kruger P., Laurie G., Saylor E., Meyer J., Venz E., Wetzig K., French C., McGain F., Mulder J., Fennessy G., Koottayi S., Bates S., Towns M., Morgan R., Tippett A., Udy A., Mason C., Licari E., Gantner D., McClure J., Nichol A., McCracken P., Board J., Martin E., Vallance S., Young M., Vladic C., McGloughlin S., Gattas D., Buhr H., Coles J., Hutch D., Wun J., Cole L., Whitehead C., Lowrey J., Masters K., Gresham R., Campbell V., Gutierrez D., Brailsford J., Forbes L., Murray L., Maguire T., NiChonghaile M., Orford N., Bone A., Elderkin T., Salerno T., Chimunda T., Fletcher J., Broadfield E., Porwal S., Knott C., Boschert C., Smith J., Richardson A., Hill D., Duke G., Oziemski P., Cegarra S., Chan P., Welsh D., Hunter S., Roodenburg O., Dyett J., Kokotsis N., Moser M., Yang Y., Padayachee L., Vetro J., Gangopadhyay H., Kaufman M., Ghosh A., Said S., Patel A., Bihari S., Matheson E., Jin X., Shrestha T., Schwartz K., Gallagher M.P., Cross R., Cheung W., Wong H., Kol M., Shah A., Wang A.Y., Bradford C., Janin P., Finfer S., Diel N., Gatward J., Hammond N., Delaney A., Bass F., Yarad E., Buscher H., Reynolds C., Baker N., Joannidis M., Bellmann R., Peer A., Hasslacher J., Koglberger P., Klein S., Zotter K., Brandtner A., Finkenstedt A., Ditlbacher A., Hartig F., Fries D., Bachler M., Schenk B., Wagner M., Eller P., Staudinger T., Tiller E., Schellongowski P., Bojic A., Hoste E.A., Bracke S., De Crop L., Vermeiren D., Thome F., Chiella B., Fendt L., Antunes V., Lafrance J.P., Lamontagne F., D'Aragon F., St-Arnaud C., Mayette M., Carbonnaeu É., Marchand J., Masse M.H., Ladouceur M., Turgeon A.F., Lauzier F., Bellemare D., Francoeur C.L., LeBlanc G., Guilbault G., Grenier S., Cloutier E., Boivin A., Delisle-Thibault C., Giannakouros P., Costerousse O., Cailhier J.F., Carrier F.M., Ghamraoui A., Lebrasseur M., Benettaib F., Salamé M., Boumahni D., Sia Y.T., Naud J.F., Roy I., Manns B.J., Duggan S., Carney D., Barchard J., Whitlock R.P., Belley-Cote E., Savija N., Sabev A., Campbell T., Creary T., Devereaux K., Brodutch S., Rigatto C., Paunovic B., Mooney O., Glybina A., Harasemiw O., Di Nella M., Harmon J., Mehta N., Lakatos L., Haslam N., Lellouche F., Simon M., Tung Y., Lizotte P., Bourchard P.A., Rochwerg B., Karachi T., Millen T., Muscedere J., Maslove D., Boyd J.G., Sibley S., Drover J., Hunt M., Georgescu I., Wax R., Lenga I., Sridhar K., Steele A., Fusco K., Ghate T., Tolibas M., Robinson H., Weir M.A., Taneja R., Ball I.M., Garg A., Campbell E., Ovsenek A., Bagshaw S.M., van Diepen S., Baig N., Magder S., Yao H., Alam A., Campisi J., MacIntyre E., Rokosh E., Scherr K., Lapinsky S., Mehta S., Shah S., Niven D.J., Stelfox H.T., Ruddell S., Russell M., Jim K., Brown G., Oxtoby K., Hall A., Benoit L., Sokolowski C., Prasad B., Giebel S., Kutsogiannis D.J., Thompson P., Thompson T., Cirone R., Kavikondala K., Soth M., Clarke F., Takaoka A., Wald R., Mazer D., Burns K., Friedrich J., Klein D., Sandhu G., Santos M., Khalid I., Hodder J., Dodek P., Ayas N., Alcuaz V., Suen G., Rewa O., Singh G., Norris S., Gibson N., Arias C., Shami A., Pelletier C., Adhikari NKJ, Zahirieh A., Amaral A., Marinoff N., Kaur N., Perez A., Wang J., Haljan G., Condin C., McIntyre L., Gomes B., Porteous R., Watpool I., Hiremath S., Clark E., Herridge M.S., Backhouse F., Wilcox M.E., Walczak K., Ki V., Sharman A., Romano M., Gibney RTN, Romanovsky A.S., McCoshen L., Wood G., Ovakim D., Auld F., Carney G., Duan M., Ji X., Guo D., Qi Z., Lin J., Zhang M., Dong L., Liu J., Liu P., Zhi D., Bai G., Qiu Y., Yang Z., Bai J., Liu Z., Zhuang H., Wang H., Li J., Zhao M., Zhou X., Shi X., Ye B., Liu M., Wu J., Fu Y., Long D., Pan Y., Wang J., Mei H., Zhang S., Wen M., Yang E., Mu S., Li J., Hu T., Qin B., Li M., Wang C., Dong X., Wang K., Wang H., Yang J., Du B., Wang C., Wang D., Li N., Yu Z., Xu S., Yao L., Hou G., Liu Z., Lu L., Lian Y., Wang C., Zhang J., Ding R., Qi G., Wang Q., Wang P., Meng Z., Chen M., Hu X., He X., Zhao S., Hang L., Li R., Qin S., Lu K., Dun S., Liu C., Zhou Q., Chen Z., Mei J., Zhang M., Xu H., Lin J., Shi Q., Fu L., Zeng Q., Ma H., Yan J., Gao L., Liu H., Zhang L., Li H., He X., Fan J., Guo L., Liu Y., Wang X., Sun J., Liu Z., Yang J., Ding L., Sheng L., Liu X., Yan J., Wang Q., Wang Y., Zhao D., Zhao S., Hu C., Li J., Deng F., Qui H., Yang Y., Mo M., Pan C., Wu C., Huang Y., Huang L., Liu A., Pettilä V., Vaara S.T., Korhonen A.M., Törnblom S., Sutinen S., Pettilä L., Heinonen J., Lappi E., Suhonen T., Karlsson S., Hoppu S., Jalkanen V., Kuitunen A., Levoranta M., Långsjö J., Ristimäki S., Malila K., Wootten A., Varila S., Järvisalo M.J., Inkinen O., Kentala S., Leivo K., Haltia P., Dreyfuss D., Ricard J.D., Messika J., Tiagarajah A., Emery M., Dechanet A., Gernez C., Roux D., Martin-Lefevre L., Fiancette M., Vinatier I., Lacherade J.C., Colin G., Lebert C., Azais M.A., Yehia A., Pouplet C., Henry-Lagarrigue M., Seguin A., Crosby L., Maizel J., Titeca-Beauport D., Demoule A., Mayaux J., Dres M., Morawiec E., Decalvele M., Demiri S., Faure M., Marios C., Mallet M., Ordon M.A., Morizot L., Cantien M., Pousset F., Gaudry S., Poirson F., Cohen Y., Argaud L., Cour M., Bitker L., Simon M., Hernu R., Baudry T., De La Salle S., Robine A., Sedillot N., Tchenio X., Bouisse C., Roux S., Barbar S.D., Trusson R., Tamion F., Grangé S., Carpentier D., Chevrel G., Ensenyat-Martin L., Marque S., Quenot J.P., Andreu P., Dargent A., Large A., Chudeau N., Landais M., Derrien B., Callahan J.C., Guitton C., Le Moal C., Robert A., Asehnoune K., Cinotti R., Grillot N., Demeure D., Vinsonneau C., Rahmani I., Marzouk M., Dekeyser T., Sejourne C., Verlay M., Thevenin F., Delecolle L., Thevenin D., Souweine B., Coupez E., Adda M., Eraldi J.P., Marchalot A., De Prost N., Mekontso Dessap A., Razazi K., Meziani F., Boisrame-Helms J., Clere-Jehl R., Delabranche X., Kummerlen C., Merdji H., Monnier A., Rabouel Y., Rahmani H., Allam H., Chenaf S., Franja V., Pons B., Carles M., Martino F., Richard R., Zuber B., Lacave G., Lakhal K., Rozec B., Van H.D., Boulet É., Fadel F., Cleophax C., Dufour N., Grant C., Thuong M., Reignier J., Canet E., Nicolet L., Boulain T., Nay M.A., Benzekri D., Barbier F., Bretagnol A., Kamel T., Mathonnet A., Muller G., Skarzynski M., Rossi J., Pradet A., Dos Santos S., Guery A., Muller L., Felix L., Bohé J., Thiéry G., Aissaoui N., Vimpere D., Commeureuc M., Diehl J.L., Guerot E., Combes A., Nieszkowska A., Masi P., Liangos O., Wittig M., Zarbock A., Küllmar M., van Waegeningh T., Rosenow N., Nichol A.D., Brickell K., Doran P., Murray P.T., Landoni G., Lembo R., Zangrillo A., Monti G., Tozzi M., Marzaroli M., Lombardi G., Paternoster G., Vitiello M., McGuinness S., Parke R., Butler M., Gilder E., Cowdrey K.A., Wallace S., Hallion J., Woolett M., Neal P., Duffy K., Long S., McArthur C., Simmonds C., Chen Y., McConnochie R., Newby L., Knight D., Henderson S., Mehrtens J., Morgan S., Morris A., Vander Hayden K., Burke T., Bailey M., Freebairn R., Chadwick L., Park P., Rolls C., Thomas L., Buehner U., Williams E., Albrett J., Kirkham S., Jackson C., Browne T., Goodson J., Jackson D., Houghton J., Callender O., Higson V., Keet O., Dominy C., Young P., Hunt A., Judd H., Lawrence C., Olatunji S., Robertson Y., Latimer-Bell C., Hendry D., Mckay-Vucago A., Beehre N., Lesona E., Navarra L., Robinson C., Jang R., Junge A., Lambert B., Schneider A.G., Thibault M., Eckert P., Kissling S., Polychronopoulos E., Poli E., Altarelli M., Schnorf M., Abed Mallaird S., Heidegger C., Perret A., Montillier P., Sangla F., Neils S., De Watteville A., Phull M.K., George A., Hussain N., Pogreban T., Lobaz S., Daniels A., Cunningham M., Kerr D., Nicholson A., Shanmugasundaram P., Abrams J., Manso K., Hambrook G., McKerrow E., Salva J., Foulkes S., Wise M., Morgan M., Brooks J., Cole J., Davies T.M., Hill H., Thomas E., Vizcaychipi M., Baharlo B., Carungcong J., Costa P., Martins L., Kapoor R., Hazelton T., Moon A., Musselwhite J., Shelley B., McCall P., Ostermann M., Arbane G., Bociek A., Marotti M., Lim R., Campos S., Grau Novellas N., Cennamo A., Slack A., Wyncoll D., Camporota L., Sparkes S., Tilley R., Rattray A., Moreland G., Duffy J., McGonigal E., Hopkins P., Finney C., Smith J., Noble H., Watson H., Harris C.L., Clarey E., Corcoran E., Beck J., Howcroft C., Youngs N., Wilby E., Ogg B., Wolverson A., Lee S., Butler S., Okubanjo M., Hindle J., Welters I., Williams K., Johnson E., Patrick-Heselton J., Shaw D., Waugh V., Stewart R., Mwaura E., Wren L., Mew L., Sutherland S.B., Adderley J., Ruddy J., Harkins M., Kaye C., Scott T., Mitchell W., Anderson F., Willox F., Jagannathan V., Clark M., Purv S., Sharman A., Meredith M., Ryan L., Conner L., Peters C., Harvey D., Roshdy A., Collins A., Sim M., Henderson S., Chee N., Pitts S., Bowman K., Dilawershah M., Vamplew L., Howe E., Rogers P., Hernandez C., Prendergast C., Benton J., Rosenberg A., Forni L.G., Grant A., Carvelli P., Raithatha A., Bird S., Richardson M., Needham M., Hirst C., Ball J., Leaver S., Howlett L., Castro Delgado C., Farnell-Ward S., Farrah H., Gray G., Joseph G., Robinson F., Tridente A., Harrop C., Shuker K., McLaughlan D., Ramsey J., Meehan S., Rose B.O., Reece-Anthony R., Gurung B., Whitehouse T., Snelson C., Veenith T., Johnston A., Cooper L., Carrera R., Ellis K., Fellows E., Harkett S., Bergin C., Spruce E., Despy L., Goundry S., Dooley N., Mason T., Clark A., Dignam G., Ward G., Attwood B., Parsons P., Mason S., Margarson M., Lord J., McGlone P., Hodgson L.E., Chadbourn I., Gomez R., Margalef J., Pretorius R., Hamshere A., Carter J., Cahill H., Grainger L., Howard K., Forshaw G., Guy Z., Kashani K.B., Albright R.C., Amsbaugh A., Stoltenberg A., Niven A.S., Lynch M., O'Mara A., Naeem S., Sharif S., McKenney Goulart J., Tolwani A., Lyas C., Latta L., Bihorac A., Hashemighouchani H., Efron P., Ruppert M., Cupka J., Kiley S., Carson J., White P., Omalay G., Brown S., Velez L., Marceron A., Neyra J.A., Aycinena J.C., Elias M., Ortiz-Soriano V.M., Hauschild C., Dorfman R.
ISSN
1533-4406 (Electronic)
ISSN-L
0028-4793
Publication state
Published
Issued date
16/07/2020
Peer-reviewed
Oui
Volume
383
Number
3
Pages
240-251
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Abstract
Acute kidney injury is common in critically ill patients, many of whom receive renal-replacement therapy. However, the most effective timing for the initiation of such therapy remains uncertain.
We conducted a multinational, randomized, controlled trial involving critically ill patients with severe acute kidney injury. Patients were randomly assigned to receive an accelerated strategy of renal-replacement therapy (in which therapy was initiated within 12 hours after the patient had met eligibility criteria) or a standard strategy (in which renal-replacement therapy was discouraged unless conventional indications developed or acute kidney injury persisted for >72 hours). The primary outcome was death from any cause at 90 days.
Of the 3019 patients who had undergone randomization, 2927 (97.0%) were included in the modified intention-to-treat analysis (1465 in the accelerated-strategy group and 1462 in the standard-strategy group). Of these patients, renal-replacement therapy was performed in 1418 (96.8%) in the accelerated-strategy group and in 903 (61.8%) in the standard-strategy group. At 90 days, death had occurred in 643 patients (43.9%) in the accelerated-strategy group and in 639 (43.7%) in the standard-strategy group (relative risk, 1.00; 95% confidence interval [CI], 0.93 to 1.09; P = 0.92). Among survivors at 90 days, continued dependence on renal-replacement therapy was confirmed in 85 of 814 patients (10.4%) in the accelerated-strategy group and in 49 of 815 patients (6.0%) in the standard-strategy group (relative risk, 1.74; 95% CI, 1.24 to 2.43). Adverse events occurred in 346 of 1503 patients (23.0%) in the accelerated-strategy group and in 245 of 1489 patients (16.5%) in the standard-strategy group (P<0.001).
Among critically ill patients with acute kidney injury, an accelerated renal-replacement strategy was not associated with a lower risk of death at 90 days than a standard strategy. (Funded by the Canadian Institutes of Health Research and others; STARRT-AKI ClinicalTrials.gov number, NCT02568722.).
We conducted a multinational, randomized, controlled trial involving critically ill patients with severe acute kidney injury. Patients were randomly assigned to receive an accelerated strategy of renal-replacement therapy (in which therapy was initiated within 12 hours after the patient had met eligibility criteria) or a standard strategy (in which renal-replacement therapy was discouraged unless conventional indications developed or acute kidney injury persisted for >72 hours). The primary outcome was death from any cause at 90 days.
Of the 3019 patients who had undergone randomization, 2927 (97.0%) were included in the modified intention-to-treat analysis (1465 in the accelerated-strategy group and 1462 in the standard-strategy group). Of these patients, renal-replacement therapy was performed in 1418 (96.8%) in the accelerated-strategy group and in 903 (61.8%) in the standard-strategy group. At 90 days, death had occurred in 643 patients (43.9%) in the accelerated-strategy group and in 639 (43.7%) in the standard-strategy group (relative risk, 1.00; 95% confidence interval [CI], 0.93 to 1.09; P = 0.92). Among survivors at 90 days, continued dependence on renal-replacement therapy was confirmed in 85 of 814 patients (10.4%) in the accelerated-strategy group and in 49 of 815 patients (6.0%) in the standard-strategy group (relative risk, 1.74; 95% CI, 1.24 to 2.43). Adverse events occurred in 346 of 1503 patients (23.0%) in the accelerated-strategy group and in 245 of 1489 patients (16.5%) in the standard-strategy group (P<0.001).
Among critically ill patients with acute kidney injury, an accelerated renal-replacement strategy was not associated with a lower risk of death at 90 days than a standard strategy. (Funded by the Canadian Institutes of Health Research and others; STARRT-AKI ClinicalTrials.gov number, NCT02568722.).
Pubmed
Create date
24/07/2020 11:07
Last modification date
20/01/2021 6:26
Usage data
